IL291864A - Combinations of cannabinoids and acyl-ethanol-amines - Google Patents

Combinations of cannabinoids and acyl-ethanol-amines

Info

Publication number
IL291864A
IL291864A IL291864A IL29186422A IL291864A IL 291864 A IL291864 A IL 291864A IL 291864 A IL291864 A IL 291864A IL 29186422 A IL29186422 A IL 29186422A IL 291864 A IL291864 A IL 291864A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
salt
cannabinoid
acylethanolamine
pea
Prior art date
Application number
IL291864A
Other languages
English (en)
Hebrew (he)
Inventor
Shmulewitz Ascher
Haber Elran
Brener Ephraim
Original Assignee
Scisparc Ltd
Shmulewitz Ascher
Haber Elran
Brener Ephraim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd, Shmulewitz Ascher, Haber Elran, Brener Ephraim filed Critical Scisparc Ltd
Publication of IL291864A publication Critical patent/IL291864A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
IL291864A 2015-04-29 2016-04-19 Combinations of cannabinoids and acyl-ethanol-amines IL291864A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Publications (1)

Publication Number Publication Date
IL291864A true IL291864A (en) 2022-06-01

Family

ID=57199061

Family Applications (2)

Application Number Title Priority Date Filing Date
IL291864A IL291864A (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and acyl-ethanol-amines
IL255238A IL255238B (en) 2015-04-29 2017-10-24 Combinations of cannabinoids and n-acylethanolamines

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL255238A IL255238B (en) 2015-04-29 2017-10-24 Combinations of cannabinoids and n-acylethanolamines

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP3288553B1 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN107530317A (enExample)
AU (4) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6938465B2 (ja) * 2015-04-29 2021-09-22 エスシーアイ スパーク リミティド カンナビノイドとｎ−アシルエタノールアミンの組み合わせ
WO2019136351A1 (en) * 2018-01-05 2019-07-11 Altus Labs, Llc Personal care compositions
US20220000833A1 (en) * 2018-01-29 2022-01-06 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
MX2020010424A (es) * 2018-04-03 2021-01-15 Pure Green Pharmaceuticals Inc Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
WO2020214569A1 (en) * 2019-04-15 2020-10-22 Metagenics, Inc. Novel hemp and pea formulation and its use
MX2021012892A (es) * 2019-04-23 2021-11-17 Scisparc Ltd Composiciones y metodos para potenciar derivados de 4-aminofenoles.
EP3965789A4 (en) * 2019-05-07 2023-01-25 Ojai Energetics PBC PROCEDURE FOR OPTIMIZING CANNABINOID DOSAGE DETERMINATION
EP3972573A4 (en) 2019-05-23 2023-07-12 India Globalization Capital, Inc. COMPOSITIONS AND METHODS OF USING CANNABINOIDS TO TREAT STAMMING/STOMMING AND SYMPTOMS OF TOURETTE SYNDROME
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR TREATING A CONDITION CHARACTERIZED BY ANANDAMID DEFICIENCY AND USES THEREOF
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
WO2021141963A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
EP4274573A4 (en) 2021-01-11 2024-12-11 Pacira Pharmaceuticals, Inc. TREATMENT OF HIP PAIN WITH LIPOSOMAL SUSTAINED-RELEASE ANESTHESIA COMPOSITIONS
WO2023278768A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
US20090054526A1 (en) 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
ES2548190T3 (es) * 2009-09-07 2015-10-14 Epitech Group S.P.A. Composición que contiene palmitoiletanolamida ultramicronizada
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
JP6938465B2 (ja) * 2015-04-29 2021-09-22 エスシーアイ スパーク リミティド カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Also Published As

Publication number Publication date
AU2016254685B2 (en) 2021-04-22
EP3288553B1 (en) 2022-12-28
WO2016174661A1 (en) 2016-11-03
JP6938465B2 (ja) 2021-09-22
CN116549437A (zh) 2023-08-08
US20220071949A1 (en) 2022-03-10
EP3288553A4 (en) 2018-12-26
ES2935605T3 (es) 2023-03-08
JP2021107401A (ja) 2021-07-29
US20200022946A1 (en) 2020-01-23
US20220071948A1 (en) 2022-03-10
CN107530317A (zh) 2018-01-02
AU2023251426A1 (en) 2023-11-09
CA2984088A1 (en) 2016-11-03
IL255238B (en) 2022-05-01
EP3288553A1 (en) 2018-03-07
US20200030281A1 (en) 2020-01-30
US20180078523A1 (en) 2018-03-22
MA41997A (fr) 2021-03-31
JP2018514589A (ja) 2018-06-07
AU2021206784B2 (en) 2023-07-20
IL255238A0 (en) 2017-12-31
AU2025287414A1 (en) 2026-01-22
AU2016254685A1 (en) 2017-11-09
US11197845B2 (en) 2021-12-14
US20210393577A1 (en) 2021-12-23
EP4193993A3 (en) 2023-07-19
AU2021206784A1 (en) 2021-08-12
US11234956B2 (en) 2022-02-01
CA2984088C (en) 2024-04-09
DK3288553T3 (da) 2023-01-23
US20200038367A1 (en) 2020-02-06
US11207290B2 (en) 2021-12-28
EP4193993A2 (en) 2023-06-14
AU2023251426B2 (en) 2025-11-27
PL3288553T3 (pl) 2023-03-20

Similar Documents

Publication Publication Date Title
FI3743053T3 (fi) Kannabinoidien käyttö epilepsian hoidossa
FI3641819T3 (fi) Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
Zhao et al. Gambogenic acid induces Noxa-mediated apoptosis in colorectal cancer through ROS-dependent activation of IRE1α/JNK
FI3710058T3 (fi) Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään
EP2609928A3 (en) Use of cannabinoids in combination with an anti-psychotic medicament
BR112021022139A2 (pt) Preparação de canabidiol, e, método para tratar um paciente que sofre de espasmos epilépticos
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
WO2009043395A3 (en) Pharmaceutical composition
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
GB201116789D0 (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)
GB201111261D0 (en) Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
PE20200677A1 (es) Composicion de cannabis
JP2021535935A5 (enExample)
HRP20201506T1 (hr) Uporaba kanabidiolne kiseline u liječenju epilepsije
JP2010524912A5 (enExample)
BR112012007206A2 (pt) dispositivo de distribuição de fármacos
CA2582289C (en) Inhibition of tumour cell migration
WO2007124489A3 (en) Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
US10596159B2 (en) Method and composition for treating cachexia and eating disorders
WO2022167822A3 (en) A cannabinoid mixture
RU2020115363A (ru) Каннабиноидная композиция и способ ее применения
GEP20115218B (en) Combination drug
WO2008113100A1 (en) Method for inducing autophagy